UA130727C2 - Сполуки тетрагідропіразоло-піразиніл-дигідроімідазо або тетрагідропіразоло-піридиніл-дигідроімідазо та способи їхнього застосування - Google Patents
Сполуки тетрагідропіразоло-піразиніл-дигідроімідазо або тетрагідропіразоло-піридиніл-дигідроімідазо та способи їхнього застосуванняInfo
- Publication number
- UA130727C2 UA130727C2 UAA202300616A UAA202300616A UA130727C2 UA 130727 C2 UA130727 C2 UA 130727C2 UA A202300616 A UAA202300616 A UA A202300616A UA A202300616 A UAA202300616 A UA A202300616A UA 130727 C2 UA130727 C2 UA 130727C2
- Authority
- UA
- Ukraine
- Prior art keywords
- butyl
- butoxy
- methyl
- compound
- propyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020102955 | 2020-07-20 | ||
| CN2021070120 | 2021-01-04 | ||
| PCT/CN2021/107216 WO2022017338A1 (en) | 2020-07-20 | 2021-07-20 | Tetrahydropyrazolo-pyrazinyl-dihydroimidazolone or tetrahydropyrazolo-pyridinyl-dihydroimidazolone compounds and methods of using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA130727C2 true UA130727C2 (uk) | 2026-04-29 |
Family
ID=77167918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA202300616A UA130727C2 (uk) | 2020-07-20 | 2021-07-20 | Сполуки тетрагідропіразоло-піразиніл-дигідроімідазо або тетрагідропіразоло-піридиніл-дигідроімідазо та способи їхнього застосування |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US12037339B2 (https=) |
| EP (1) | EP4182020A1 (https=) |
| JP (3) | JP7569443B2 (https=) |
| KR (2) | KR102936860B1 (https=) |
| CN (1) | CN116390926A (https=) |
| AU (2) | AU2021311567B2 (https=) |
| BR (1) | BR112023000932A2 (https=) |
| CA (1) | CA3186217A1 (https=) |
| CL (1) | CL2023000196A1 (https=) |
| CO (1) | CO2023001407A2 (https=) |
| IL (1) | IL299704A (https=) |
| MX (1) | MX2023000943A (https=) |
| PE (1) | PE20230854A1 (https=) |
| PH (1) | PH12023550130A1 (https=) |
| UA (1) | UA130727C2 (https=) |
| WO (1) | WO2022017338A1 (https=) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190060A1 (ar) | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
| CN116368140A (zh) * | 2020-09-10 | 2023-06-30 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| US12479854B2 (en) | 2021-07-29 | 2025-11-25 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| WO2023016546A1 (en) * | 2021-08-12 | 2023-02-16 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| PT4408840T (pt) | 2021-09-27 | 2025-10-07 | Terns Pharmaceuticals Inc | Ácidos benzimidazolocarboxílicos como agonistas de glp-1r |
| CN118401519A (zh) | 2021-10-25 | 2024-07-26 | 拓臻制药公司 | 作为glp-1r激动剂的化合物 |
| CN119095843A (zh) | 2022-02-23 | 2024-12-06 | 拓臻制药公司 | 作为glp-1r激动剂的化合物 |
| EP4522131A1 (en) * | 2022-05-11 | 2025-03-19 | Eli Lilly and Company | Glp1 tablet compositions |
| CN116003403B (zh) * | 2022-11-20 | 2024-07-23 | 药康众拓(北京)医药科技有限公司 | 一种氘代吲唑类化合物、药物组合物及其应用 |
| IL321043A (en) * | 2022-12-15 | 2025-07-01 | Sironax Ltd | SARM1 modulators, their preparations and uses |
| EP4652167A1 (en) * | 2023-01-17 | 2025-11-26 | Fochon Biosciences, Ltd. | Glp-1r agonists and uses thereof |
| CN120957993A (zh) | 2023-02-16 | 2025-11-14 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| EP4568664B1 (en) | 2023-04-07 | 2026-04-01 | Terns Pharmaceuticals, Inc. | Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity |
| WO2025002250A1 (zh) * | 2023-06-29 | 2025-01-02 | 韦恩生物科技有限公司 | 一种glp-1受体激动剂及其制备方法和用途 |
| IL325536A (en) * | 2023-06-30 | 2026-02-01 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | A compound containing a multi-fused ring structure |
| WO2025011664A1 (zh) | 2023-07-12 | 2025-01-16 | 歌礼制药(中国)有限公司 | Glp-1r激动剂的制剂及其制备方法 |
| TW202508571A (zh) * | 2023-07-28 | 2025-03-01 | 大陸商上海翰森生物醫藥科技有限公司 | 一種苯并含氮雜環類衍生物調節劑、其製備方法和應用 |
| WO2025026436A1 (zh) * | 2023-08-02 | 2025-02-06 | 韦恩生物科技有限公司 | 一种含氮并环化合物及其制备方法和用途 |
| WO2025045208A1 (en) * | 2023-08-31 | 2025-03-06 | Gasherbrum Bio, Inc. | Heteroaryl-heterocycloalkyl-based glp-1 agonists |
| CN120981457A (zh) * | 2023-09-14 | 2025-11-18 | 歌礼制药(中国)有限公司 | Glp-1r激动剂及其治疗方法 |
| CN121941685A (zh) | 2023-11-10 | 2026-04-28 | 重庆药友制药有限责任公司 | 一种glp-1r激动剂化合物及其应用 |
| TW202527933A (zh) * | 2023-11-16 | 2025-07-16 | 大陸商西藏海思科製藥有限公司 | 咪唑-2-酮衍生物及其在醫藥上的應用 |
| TW202540124A (zh) * | 2023-11-21 | 2025-10-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 雜環類化合物、其製備方法及其在醫藥上的應用 |
| TW202521534A (zh) * | 2023-11-24 | 2025-06-01 | 香港商歌禮製藥(中國)有限公司 | Glp-1r 激動劑及其治療方法 |
| TW202542146A (zh) * | 2023-12-05 | 2025-11-01 | 大陸商信達生物科技有限公司 | 靶向ｇｌｐ－１受體的化合物以及其用途 |
| WO2025124357A1 (zh) * | 2023-12-14 | 2025-06-19 | 广东众生睿创生物科技有限公司 | 一种杂环glp-1受体激动剂及其应用 |
| TW202527937A (zh) * | 2023-12-22 | 2025-07-16 | 大陸商石藥集團百克（山東）生物製藥股份有限公司 | 多環化合物及其用途 |
| CN117447493A (zh) * | 2023-12-25 | 2024-01-26 | 药康众拓(北京)医药科技有限公司 | 氘代吲哚嗪类化合物、药物组合物及其应用 |
| CN117777111A (zh) * | 2023-12-26 | 2024-03-29 | 上海苏博医药科技有限公司 | 一种Orforglipron关键中间体的合成方法及其中间体 |
| WO2025148997A1 (zh) * | 2024-01-10 | 2025-07-17 | 海思科医药集团股份有限公司 | 一种四氢吡啶并吡唑衍生物及其在医药上的应用 |
| WO2025158275A1 (en) | 2024-01-24 | 2025-07-31 | Pfizer Inc. | Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds |
| WO2025162065A1 (zh) * | 2024-01-30 | 2025-08-07 | 海创药业股份有限公司 | 一种具有glp-1受体激动剂作用的小分子化合物及其用途 |
| WO2025175249A1 (en) | 2024-02-14 | 2025-08-21 | Olema Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
| WO2025176130A1 (zh) * | 2024-02-19 | 2025-08-28 | 上海壹迪生物技术有限公司 | 一种含吡唑并环类化合物、其药物组合物及其用途 |
| TW202600132A (zh) | 2024-03-08 | 2026-01-01 | 美商安尼波那生物公司 | 用於治療肥胖症及提高減重之方法 |
| TW202602880A (zh) * | 2024-03-29 | 2026-01-16 | 美商拜歐美亞富成股份有限公司 | 雜環glp-1r促效劑 |
| WO2025209515A1 (zh) * | 2024-04-03 | 2025-10-09 | 广州市联瑞制药有限公司 | 一种glp-1受体激动剂及其制备方法和应用 |
| WO2025237355A1 (zh) * | 2024-05-17 | 2025-11-20 | 成都地奥九泓制药厂 | 一种glp-1受体激动剂化合物、其制备方法及其应用 |
| WO2025247390A1 (zh) * | 2024-05-31 | 2025-12-04 | 福佑泰生物制药公司 | 可用作glp-1r激动剂的杂双环化合物 |
| WO2025259825A1 (en) | 2024-06-12 | 2025-12-18 | Eli Lilly And Company | Glp-1 npa therapies for maintaining body weight loss or reduced hba1c levels following a prior glp-1 ra treatment |
| WO2025261454A1 (zh) * | 2024-06-19 | 2025-12-26 | 上海翰森生物医药科技有限公司 | 一种含氮大环化合物衍生物调节剂及其制备方法和应用 |
| WO2025264023A1 (en) * | 2024-06-19 | 2025-12-26 | Chong Kun Dang Pharmaceutical Corp. | Glp-1 receptor agonist, and uses thereof |
| WO2026001866A1 (zh) * | 2024-06-24 | 2026-01-02 | 联邦生物科技(珠海横琴)有限公司 | 一种glp-1受体激动剂及其应用 |
| WO2026007995A1 (zh) * | 2024-07-03 | 2026-01-08 | 成都地奥九泓制药厂 | 一种杂环类glp-1受体激动剂化合物、其制备方法及其应用 |
| WO2026012416A1 (zh) * | 2024-07-11 | 2026-01-15 | 江苏德源药业股份有限公司 | 杂环类化合物、药物组合物及其应用 |
| WO2026012449A1 (zh) * | 2024-07-12 | 2026-01-15 | 联邦生物科技(珠海横琴)有限公司 | 一种具有glp-1受体激动剂效应的杂环化合物及其应用 |
| WO2026031819A1 (en) * | 2024-08-06 | 2026-02-12 | Insilico Medicine Ip Limited | Novel compounds as glp-1r agonists and uses thereof |
| WO2026041075A1 (en) * | 2024-08-21 | 2026-02-26 | Gasherbrum Bio, Inc. | Gpl-1 agonists |
| CN119100966B (zh) * | 2024-09-02 | 2025-09-09 | 上海毕得医药科技股份有限公司 | 一种溴代吡咯甲酸甲酯的合成方法 |
| WO2026055512A1 (en) * | 2024-09-05 | 2026-03-12 | Biomea Fusion, Inc. | Combination of a menin inhibitor with a pyrazolopiperidine glp-1 receptor agonist for treating diabetes and obesity |
| WO2026052129A1 (zh) * | 2024-09-09 | 2026-03-12 | 中国科学院上海药物研究所 | 多环杂芳烃类glp-1受体激动剂 |
| CN120309500B (zh) * | 2025-06-19 | 2025-08-15 | 南昌大学 | 奥格列龙原料中间体及合成方法与奥格列龙原料合成方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| JP6278472B2 (ja) | 2013-02-27 | 2018-02-14 | 塩野義製薬株式会社 | Ａｍｐｋ活性化作用を有するインドールおよびアザインドール誘導体 |
| JOP20190060A1 (ar) | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
| JP7461104B2 (ja) | 2017-11-29 | 2024-04-03 | 中外製薬株式会社 | Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物 |
| EP3759110A1 (en) * | 2018-02-28 | 2021-01-06 | Novartis AG | Indole-2-carbonyl compounds and their use for the treatment of hepatitis b |
-
2021
- 2021-07-20 US US17/380,084 patent/US12037339B2/en active Active
- 2021-07-20 AU AU2021311567A patent/AU2021311567B2/en active Active
- 2021-07-20 MX MX2023000943A patent/MX2023000943A/es unknown
- 2021-07-20 CA CA3186217A patent/CA3186217A1/en active Pending
- 2021-07-20 EP EP21749074.7A patent/EP4182020A1/en active Pending
- 2021-07-20 WO PCT/CN2021/107216 patent/WO2022017338A1/en not_active Ceased
- 2021-07-20 BR BR112023000932A patent/BR112023000932A2/pt unknown
- 2021-07-20 PH PH1/2023/550130A patent/PH12023550130A1/en unknown
- 2021-07-20 JP JP2023504008A patent/JP7569443B2/ja active Active
- 2021-07-20 IL IL299704A patent/IL299704A/en unknown
- 2021-07-20 KR KR1020237005845A patent/KR102936860B1/ko active Active
- 2021-07-20 KR KR1020267006827A patent/KR20260040657A/ko active Pending
- 2021-07-20 UA UAA202300616A patent/UA130727C2/uk unknown
- 2021-07-20 PE PE2023000103A patent/PE20230854A1/es unknown
- 2021-07-20 CN CN202180063652.8A patent/CN116390926A/zh active Pending
- 2021-11-02 US US17/516,932 patent/US11584751B1/en active Active
-
2023
- 2023-01-19 CL CL2023000196A patent/CL2023000196A1/es unknown
- 2023-02-09 CO CONC2023/0001407A patent/CO2023001407A2/es unknown
-
2024
- 2024-05-14 US US18/663,450 patent/US20250059192A1/en active Pending
- 2024-10-04 JP JP2024174734A patent/JP7795064B2/ja active Active
-
2025
- 2025-09-24 AU AU2025237942A patent/AU2025237942A1/en active Pending
- 2025-11-28 JP JP2025207454A patent/JP2026035735A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023000932A2 (pt) | 2023-10-03 |
| PH12023550130A1 (en) | 2024-06-24 |
| AU2025237942A1 (en) | 2025-10-16 |
| IL299704A (en) | 2023-03-01 |
| WO2022017338A1 (en) | 2022-01-27 |
| JP7795064B2 (ja) | 2026-01-07 |
| AU2021311567A1 (en) | 2023-02-16 |
| JP2026035735A (ja) | 2026-03-04 |
| CN116390926A (zh) | 2023-07-04 |
| US20250059192A1 (en) | 2025-02-20 |
| PE20230854A1 (es) | 2023-05-29 |
| US11584751B1 (en) | 2023-02-21 |
| KR20230048056A (ko) | 2023-04-10 |
| MX2023000943A (es) | 2023-02-22 |
| EP4182020A1 (en) | 2023-05-24 |
| CL2023000196A1 (es) | 2023-09-15 |
| AU2021311567B2 (en) | 2025-07-10 |
| CO2023001407A2 (es) | 2023-02-16 |
| JP2025004124A (ja) | 2025-01-14 |
| US12037339B2 (en) | 2024-07-16 |
| US20230051320A1 (en) | 2023-02-16 |
| JP7569443B2 (ja) | 2024-10-17 |
| KR20260040657A (ko) | 2026-03-25 |
| KR102936860B1 (ko) | 2026-03-12 |
| CA3186217A1 (en) | 2022-01-27 |
| JP2023534983A (ja) | 2023-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA130727C2 (uk) | Сполуки тетрагідропіразоло-піразиніл-дигідроімідазо або тетрагідропіразоло-піридиніл-дигідроімідазо та способи їхнього застосування | |
| AU2022260487B2 (en) | Carboxy-benzimidazole glp-1r modulating compounds | |
| CA2877550C (en) | Imidazopyridine derivatives as modulators of tnf activity | |
| US10426135B2 (en) | Methyl- and trifluromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof | |
| KR102731924B1 (ko) | 파르네소이드 x 수용체 조정제로서의 스피로시클릭 화합물 | |
| JP2021535164A (ja) | 心筋サルコメア阻害剤 | |
| CA3088548A1 (en) | Aminopyrrolotriazines as kinase inhibitors | |
| TW202400561A (zh) | Lpa受體拮抗劑及其用途 | |
| EP3870578A1 (en) | Therapeutic compounds | |
| KR20250023365A (ko) | 알파 4 베타 7 인테그린 조정제 및 그의 용도 | |
| US12570655B2 (en) | Cysteine covalent modifiers of AKT1 and uses thereof | |
| CN119707982A (zh) | 嘧啶并吡唑类化合物、其药物组合物及其用途 | |
| AU2024358103A1 (en) | Cysteine covalent modifiers of akt1 and uses thereof | |
| CN117510500A (zh) | 一种asperazepanones类生物碱制备方法与作为抗炎药物的应用 | |
| EA049031B1 (ru) | Соединения тетрагидропиразоло-пиразинил-дигидроимидазолона или тетрагидропиразоло-пиридинил-дигидроимидазолона и способы их применения | |
| TW202214618A (zh) | 用作免疫調節劑的化合物、包含其的藥物組合物及其用途 | |
| TW202227456A (zh) | Ａｐｏｌ１抑制劑及其使用方法 | |
| TW202409010A (zh) | 人類呼吸道融合病毒及人類間質肺炎病毒之抑制劑 | |
| HK40056262B (zh) | 治疗性化合物 |